AL
ALEMG.PA Euromedis Groupe SA
- Market cap
- EUR 15.6M
- P/E
- -
- P/B
- 0.95x
- ROE
- 76.9%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALEMG.PA undervalued?
Graham numberThe Graham number of Euromedis Groupe SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Euromedis Groupe SA fundamental analysis
3 of 11 checks passedROE 0/2
Negative ROE (-15.73%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-10.4%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
The stock's low PBV ratio (0.42x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 2/2
The stock has a low debt to equity ratio (37%), which means it has a small amount of debt compared to the ownership it holds
Revenue Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Net Profit Growth 0/2
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Graham Number 1/1
Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.
Dividend Growth 0/2
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.
Dividend 0/2
The company's lack of dividends in the past three years may concern investors seeking regular income.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (-193) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Euromedis Groupe SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Euromedis Groupe SA
Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, micro perfusionists; infusion and transfusion services, catheters, accessories, and waste collectors; disinfection, hygiene, and surface protection…
Full company profileEuromedis Groupe SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Euromedis Groupe SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 73.2M | 73.6M | 76.1M | 77.1M | 193M | 112M | 54.2M | 37.4M | 36.2M | 40.8M | 91.3M |
| Gross Profit | 27.2M | 28.1M | 26.4M | 24.9M | 64.2M | 33.5M | 18.7M | 3.57M | 1.93M | 12.3M | 1.33M |
| Operating Income | 1.29M | -244K | -2.13M | -3.67M | 28.7M | 3.70M | -5.66M | -5.73M | 397K | 313K | 1.02M |
| EBITDA | 2.93M | 618K | -397K | -1.91M | 31.0M | 4.39M | -4.51M | -5.18M | -5.38M | 875K | 7.21M |
| Net Income | 1.01M | -146K | -4.92M | -3.80M | 22.7M | 2.26M | -5.96M | 13.1M | -6.11M | -132K | 15.6M |
| EPS | 0.34 | -0.05 | -1.66 | -1.27 | 6.38 | 0.63 | -2.04 | 4.60 | -2.14 | -0.05 | 5.47 |
| Balance Sheet | |||||||||||
| Total Assets | 56.8M | 57.2M | 50.4M | 60.2M | 92.6M | 72.7M | 59.9M | 46.3M | 38.8M | 39.5M | 43.1M |
| Total Liabilities | 27.9M | 29.4M | 29.1M | 42.5M | 53.7M | 31.5M | 25.0M | 23.7M | 22.3M | 23.0M | 22.8M |
| Shareholders' Equity | 28.8M | 27.8M | 21.3M | 17.6M | 38.7M | 41.0M | 34.7M | 22.6M | 16.5M | 16.4M | 20.3M |
| Cash & Short-term Investments | 1.70M | 1.01M | 1.48M | 5.12M | 15.7M | 31.9M | 26.8M | 18.8M | 15.2M | 16.7M | 19.1M |
| Total Debt | 9.55M | 9.67M | 11.5M | 34.7M | 19.0M | 16.0M | 12.8M | 10.0M | 8.04M | 6.11M | 5.25M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.45M | 1.22M | -1.63M | 965K | 13.5M | 19.2M | -1.05M | - | - | - | - |
| Capital Expenditure | 1.36M | 1.42M | 1.38M | 1.57M | 660K | 1.84M | 1.03M | 0.00 | 0.00 | 0.00 | - |
| Free Cash Flow | 87.0K | -204K | -3.01M | -602K | 12.8M | 17.4M | -2.08M | - | - | - | - |
| Ratios | |||||||||||
| ROE | 3.5% | -0.5% | -23.1% | -21.5% | 58.5% | 5.5% | -17.2% | 58.0% | -37.1% | -0.8% | 76.9% |
| ROA | 1.8% | -0.3% | -9.8% | -6.3% | 24.5% | 3.1% | -9.9% | 28.3% | -15.7% | -0.3% | 36.3% |
| Net Profit Margin | 1.4% | -0.2% | -6.5% | -4.9% | 11.7% | 2.0% | -11.0% | 35.0% | -16.9% | -0.3% | 17.1% |
| Debt to Equity | 0.33x | 0.35x | 0.54x | 1.97x | 0.49x | 0.39x | 0.37x | 0.44x | 0.49x | 0.37x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Euromedis Groupe SA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 31, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | EUR 269K | 0.09 | - |
| 2016 | EUR 359K | 0.12 | 35.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 255:254 on Mar 3, 2011.
Who owns Euromedis Groupe SA
- Insiders 64.06%
- Institutions 1.97%
- Public & others 33.97%
- Shares outstanding 2.86M
- Free float 1.01M
Euromedis Groupe SA company profile
- Company name
- Euromedis Groupe SA
- Ticker
- ALEMG.PA
- ISIN
- FR0000075343
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 38
- Fiscal year end
- December
- Address
- ZA de la Tuilerie, Mouy, France, 60290
- Phone
- 33 3 44 73 83 60
- Website
- laboratoires-euromedis.fr
About Euromedis Groupe SA
Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, micro perfusionists; infusion and transfusion services, catheters, accessories, and waste collectors; disinfection, hygiene, and surface protection; panty liners and sanitary napkins, absorbent underwear, support briefs, and bed pad; rollators, cannes, and transfer products; heating products; daily aid; bed tables, reclining chairs, and bath and toilet products; blood pressure monitors, thermometers, pulse oximeters, and other diagnostic products; urine bags, probes, and drains; candy; and oxygen therapy products. The company was founded in 1985 and is based in Mouy, France.
Euromedis Groupe SA management
1- Mr. Mathieu RoturierChairman of the Board of Directors & CEO